- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04388683
Inhaled Nitric Oxide for Preventing Progression in COVID-19 (NO-COVID-19)
Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.
Descripción general del estudio
Descripción detallada
Primary Objective:
• To investigate the hypothesis that inhaled NO will reduce clinical worsening of hospitalized, high-risk patients with early COVID-19 to progressive systemic de-oxygenation, intubation, or death.
Secondary Objectives:
• To investigate the hypothesis that the beneficial effects of inhaled NO occur coincident with a decrease in systemic inflammation in COVID-19.
This is a pilot randomized-controlled (2:1) open label investigation of inhaled NO to prevent progression to more advanced disease in 42 hospitalized patients with COVID-19, at risk for worsening, based on baseline systemic oxygenation and 2 or more of the major risk factors of age > 60 years, type II DM, hypertension, and obesity.
We will perform computerized block randomization (on day zero) with a 2:1 study drug-to-control ratio to receive either open label pulsed inhaled nitric oxide, in addition to standard of care, or standard of care alone. Randomization will be stratified by being in clinical severity stage 1 or stage 2. Randomization will occur in blocks of 6 subjects: 4 iNO and 2 standard of care. Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm)
The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization ("day 1"), we will be calculate clinical score, daily, as the average of 3 assessments made within 2 hour windows.
The patient will be followed, and clinical stage determined daily, through discharge, death or 28 days post-randomization. Treatment will be given for up to 2 weeks unless patient deteriorates and requires escalation to high flow or intubation or improves and is no longer deemed to need therapy.
The following severity score 3 times daily, based on the level of oxygenation / ventilation support, where the treatment target is 92% <= O2 saturation < 96%
: Scale Title:7-Point Respiratory Severity Scale Scale Range: 0-6 Higher values = worse
Stage Oxygen support
0. Not receiving O2 supplementation; AND room air O2 saturation ≥95%
- Supplemental O2 ≤ 2 liters/min; OR room air O2 saturation ≤ 94%
- Supplemental nasal O2 >2 and <= 5 liters/min
- Supplemental nasal O2 >5 liters/min
- HFNC or NIV with FiO2 > 50%
- Intubation, ECMO, or need to intubate with "Do not intubate" order
- Death
Treatment effect will also be assessed, as a secondary endpoint, via an alternate severity scale, assigned daily from the data accrued, as above, through 14 days post-randomization or discharge.
Data from this pilot study will be used to plan future a larger randomized controlled outcome trial.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18-85 years.
- Admitted to the hospital (med-surg or critical care) with dyspnea
Diagnosis of COVID-19 based on either
- positive nasal or oral pharyngeal swab by PCR, or
- highly probable clinical picture based on clinical and CXR/CT scan
- Requiring oxygen supplementation OR O2 saturation on room air of ≤ 94%
At least 2 of the following 4 risk factors for clinical worsening:
- Age >= 60 years
- T2DM or pre-diabetes as evidenced by either treatment with a hypoglycemic agent or any documented HgA1c >= 5.6
- Obesity, based on BMI >= 30 kg/m2
- Hypertension, based on treatment with an antihypertensive medication or systolic or diastolic blood pressure measurement >= 140 or >= 90 mmHg, documented at enrollment or at any time within the prior 6 months.
Exclusion Criteria:
- Intubated or prior intubation (during present hospitalization) or anticipated intubation within the subsequent 2 hours.
- Receiving > 5L/min flow nasal O2 to maintain O2sat greater than or equal to 92%
- Using high-flow nasal cannula (HFNC) or non-invasive ventilation (NIV)
- Receiving iNO, a PDE5 inhibitor, oral or intravenous nitrates, nitroprusside, prilocaine, sulfonamides, or riociguat.
- Other major pulmonary, cardiac, such as chronic obstructive lung disease or heart failure, or systemic illness or disease involvement with potential to represent the primary driver for clinical deterioration within the next 3 days.
- History of group 1 pulmonary hypertension.
- Pregnancy
- Active breast feeding
- Severe chronic kidney disease, either receiving renal replacement therapy or eGFR < 15 ml/min/m2
- Acute kidney injury (AKI), evidenced by acute doubling of serum creatinine within previous 48 hours.
- Clinically relevant spontaneous alteration of mental state
- Inability to provide written informed consent.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Intervention
Will receive study drug treatment.
|
Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm).
The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart.
Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2).
Study drug will begin within 1 hour of randomization.
Beginning on the day following randomization ("day 1"), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM.
|
Sin intervención: Control
Will receive standard of care.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Average Maximum Disease Severity Assessed Through 28 Days
Periodo de tiempo: 28 days
|
The clinical disease severity was assessed pre-randomization as the worse of 2 scores measured 2 hours apart.
Patients eligible for randomization were those with scores of 1 or 2 (below), and randomization was stratified according to score (1 or 2).
Study drug began within 1 hour of randomization.
Beginning on the day following randomization ("day 1"), we calculated clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM.
|
28 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Mortalidad
Periodo de tiempo: 28 días
|
28 días
|
|
Days to Maximum Clinical Disease Severity Score
Periodo de tiempo: 28 days
|
The number of days for participants to reach their maximum clinical disease severity score. Severity score assessed by the following table Stage Oxygen support 0 Not receiving O2 supplementation; AND room air O2 saturation ≥95%
|
28 days
|
Days to Maximum Outcome Severity Score
Periodo de tiempo: 28 days
|
The number of days for patients to reach maximum severity score from randomization. clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM according to the following table: The following severity score 3 times daily, based on the level of oxygenation / ventilation support, where the treatment target is 92% ≤ O2 saturation < 96%: Stage Oxygen support 0 Not receiving O2 supplementation; AND room air O2 saturation ≥95%
|
28 days
|
Number of Participants in Each Stage at Maximum Severity
Periodo de tiempo: 28 days
|
Maximum outcome severity score
|
28 days
|
Length of Hospital Stay
Periodo de tiempo: 28 days
|
The numbers of days a patient spent in the hospital.
|
28 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Marvin Konstam, MD, Tufts Medical Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por coronavirus
- Infecciones por coronaviridae
- Infecciones por Nidovirales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones del Tracto Respiratorio
- Enfermedades de las vías respiratorias
- Neumonía Viral
- Neumonía
- Enfermedades pulmonares
- COVID-19
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes vasodilatadores
- Agentes Autonómicos
- Agentes del sistema nervioso periférico
- Agentes Protectores
- Agentes broncodilatadores
- Agentes antiasmáticos
- Agentes del sistema respiratorio
- Antioxidantes
- Eliminadores de radicales libres
- Factores relajantes dependientes del endotelio
- Gasotransmisores
- Óxido nítrico
Otros números de identificación del estudio
- STUDY00000554
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre COVID-19
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustTerminado
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera Niguarda... y otros colaboradoresTerminado
-
Yang I. PachankisActivo, no reclutandoInfección respiratoria por COVID-19 | Síndrome de Estrés COVID-19 | Reacción adversa a la vacuna COVID-19 | Tromboembolismo asociado a COVID-19 | Síndrome Post-Cuidados Intensivos COVID-19 | Accidente cerebrovascular asociado con COVID-19Porcelana
-
Massachusetts General HospitalReclutamientoSíndrome posagudo de COVID-19 | COVID largo | Secuelas post agudas de COVID-19 | Largo COVID-19Estados Unidos
-
Population Health Research InstituteMcMaster University; Hamilton Health Sciences CorporationTerminadoCirugía | COVID-19 | Complicación perioperatoriaCanadá
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...TerminadoSecuelas post agudas de COVID-19 | Condición posterior a COVID-19 | Largo-COVID | Síndrome crónico de COVID-19Italia
-
Indonesia UniversityReclutamientoSíndrome Post-COVID-19 | COVID largo | Condición posterior a COVID-19 | Síndrome Post-COVID | Largo COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkAún no reclutandoSíndrome Post-COVID-19 | COVID largo | Largo Covid19 | Condición posterior a COVID-19 | Síndrome Post-COVID | Condición posterior a COVID-19, no especificada | Condición post-COVIDPaíses Bajos
-
Sheba Medical CenterDesconocido
-
Jonathann Kuo, MDActivo, no reclutandoInfección por SARS-CoV2 | Síndrome Post-COVID-19 | Disautonomía | Síndrome posagudo de COVID-19 | COVID largo | Largo Covid19 | COVID-19 Recurrente | COVID-19 posagudo | Infección posaguda por COVID-19 | Secuelas post agudas de COVID-19 | Trastorno similar a la disautonomía | Disautonomía Síndrome de Hipotensión... y otras condicionesEstados Unidos